SOUTH
SAN FRANCISCO, Calif., Sept. 19,
2022 /PRNewswire/ -- IDEAYA Biosciences,
Inc. (Nasdaq:IDYA) today announced the closing of its
underwritten public offering of 8,761,905 shares of its common
stock at a public offering price of $10.50 per share, before underwriting discounts
and commissions, including the exercise in full by the underwriters
of their option to purchase up to an additional 1,142,857 shares of
common stock in the offering. The gross proceeds from the offering,
before deducting underwriting discounts and commissions and other
offering expenses payable by IDEAYA, were approximately $92.0
million.
J.P. Morgan, Jefferies, Citigroup and Guggenheim Securities
acted as joint book-running managers for the offering. Wedbush
PacGrow acted as lead manager for the offering.
The public offering was made by IDEAYA pursuant to a shelf
registration statement on Form S-3 that was previously filed with
and declared effective by the U.S. Securities and Exchange
Commission, or the SEC. The offering was made only by means of
a written prospectus and prospectus supplement that form a part of
the registration statement. A final prospectus supplement and
accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC's website
at http://www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained by request from: J.P. Morgan, by mail at J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY
11717, or by telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmorganchase.com; Jefferies, by mail at Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, New York, NY 10022, or by
telephone at 877-547-6340 or 877-821-7388, or by email at
Prospectus_Department@Jefferies.com; Citigroup, by mail at
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at 1-800-831-9146; or
Guggenheim Securities, by mail at Guggenheim Securities, LLC,
Attention: Equity Syndicate Department, 330 Madison Avenue,
New York, NY 10017, or by
telephone at (212) 518-5548 or by email at
gsequityprospectusdelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is
applying its research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301627515.html
SOURCE IDEAYA Biosciences, Inc.